Biogen Sells Samsung Bioepis Stake In $2.3bn Buyout

Samsung Biologics To Take Full Ownership Of Biosimilars Joint Venture

 
• By Dave Wallace

Biogen has struck a deal that will see it sell its equity stake in the Samsung Bioepis biosimilars joint venture to partner Samsung Biologics for up to $2.3bn.

Samsung Biologics logo website magnifying glass
Samsung Biologics has taken control of the biosimilars joint venture • Source: Dennis Diatel / Alamy Stock Photo

More from Archive

More from Generics Bulletin